Key points from article :
The Longevity Escape Velocity Foundation (LEVF) reports major progress in its mission to prevent and cure age-related disease, which accounts for roughly 70% of deaths worldwide. Rather than focusing on individual illnesses, LEVF targets the root cause of aging itself: the gradual buildup of cellular and molecular damage. Its core strategy is to repair this damage using multiple therapies at once, with the goal of extending both lifespan and healthspan—even when treatment begins in midlife.
At the heart of this effort is Robust Mouse Rejuvenation (RMR), a programme designed to show that combining several damage-repair interventions can dramatically extend the remaining lifespan of ordinary, middle-aged mice. An initial study (RMR1) found that different treatments can work additively, but four interventions were not enough to achieve full rejuvenation. A larger follow-up, RMR2, is now in its pilot phase, testing more therapies, repeating treatments over time, and carefully examining differences between male and female mice. If funding stays on track, the main study should begin in 2026, with key results expected around 2028.
LEVF also highlights wider developments from 2025. These include the launch of Aubrai, an AI bio-agent trained on the ideas of LEVF’s leadership to help accelerate longevity research and funding decisions; the public release of RAID, a database and visualization tool summarising lifespan-extending rodent studies; and growing support for the Healthspan Action Coalition, which now links hundreds of organisations worldwide to advocate for healthier aging. Together, these efforts aim to build scientific evidence and public momentum for treating aging as a solvable medical problem.
